Anticonvulsants Market Forecast 2024-2033: Growth Rate, Drivers, And Trends


Posted February 6, 2024 by ramtbrc

The anticonvulsants market size is expected to see steady growth in the next few years. It will grow to $21.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%.

 
The Anticonvulsants Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Anticonvulsants Market:
https://www.thebusinessresearchcompany.com/report/anticonvulsants-global-market-report

According to The Business Research Company’s Anticonvulsants Global Market Report 2024, The anticonvulsants market size has grown steadily in recent years. It will grow from $18.39 billion in 2023 to $19.08 billion in 2024 at a compound annual growth rate (CAGR) of 3.7%. The growth in the historic period can be attributed to risen prevalence of epilepsy, advancements in diagnostic capabilities, expanding indications, focus on personalized medicine, increased awareness and education.

The anticonvulsants market size is expected to see steady growth in the next few years. It will grow to $21.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to continuing increase in epilepsy cases, expanding applications in neuropsychiatry, development of new anticonvulsant agents, increasing emphasis on mental health, global health initiatives. Major trends in the forecast period include pediatric applications and formulations, shift towards extended-release formulations, growing adoption of generic versions, integration with digital health solutions, research on neuroprotective effects.

The rise in the prevalence of epilepsy is expected to propel the growth of the anticonvulsants market going forward. Epilepsy is a common disorder that affects the brain and frequently results in seizures. It is a chronic nontransmissible disease of the brain that affects people of all ages. Anticonvulsants are medications used to suppress seizures in people with epilepsy. Anticonvulsants help control symptoms of epilepsy by blocking the abnormal electrical activity in the brain that causes seizures and is not necessarily a cure for the disease. For instance, in February 2023, according to the World Health Organization, a Switzerland-based United Nations agency responsible for public health, globally, an estimated 5 million people are diagnosed with epilepsy yearly. The high-income countries have an estimated 49 per 0.1 million people are diagnosed with epilepsy each year, and as many as 139 per 0.1 million in low- and middle-income countries. Therefore, the rise in the prevalence of epilepsy is driving the growth of the anticonvulsants market going forward.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10682&type=smp

The anticonvulsants market covered in this report is segmented –
1) By Type: Pyrimidinediones, Benzodiazepines, Fructose Derivatives, Aromatic Allylic Alcohols, Valproylamides, Carboxamides, Bromides, Other Types
2) By Drug Generation: First Generation, Second Generation, Third Generation
3) By Dosage: Capsule, Tablet, Cream, Liquid, Rectal Gel, Other Dosages
4) By Application: Migraine, Epilepsy, Neuropathic Pain, Anxiety, Fibromyalgia, Bipolar Disorder, Borderline Personality Disorder
5) By End-User: Hospitals, Clinics, Other End-Users

Product development is a key trend gaining popularity in the anticonvulsants market. Major companies operating in the anticonvulsants market are focused on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in December 2022, Lupin Limited, an India-based pharmaceutical company, launched an abbreviated new drug application, Rufinamide tablets USP, 200 mg and 400 mg, an anticonvulsant drug. Rufinamide is used with other medications to control seizures in people who have a severe form of epilepsy called Lennox-Gastaut syndrome, which begins during childhood and causes several types of seizures, behavioral disturbances, and developmental delays in an individual.

The anticonvulsants market report table of contents includes:
1. Executive Summary
2. Anticonvulsants Market Characteristics
3. Anticonvulsants Market Trends And Strategies
4. Anticonvulsants Market - Macro Economic Scenario
5. Global Anticonvulsants Market Size and Growth
.
31. Global Anticonvulsants Market Competitive Benchmarking
32. Global Anticonvulsants Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Anticonvulsants Market
34. Anticonvulsants Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By The Business Research Company
Country United States
Categories Advertising
Tags anticonvulsants market size
Last Updated February 6, 2024